B. Riley lowered the firm’s price target on Perspective Therapeutics (CATX) to $11 from $12 and keeps a Buy rating on the shares. Ahead of the data update at ASCO 2026, the firm views Perspective Therapeutics as having a similar setup and similar competitive landscape to that Tango Therapeutics (TNGX) had five months ago, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Reports Q3 2025 Results and Clinical Progress
- Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience
- Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
- Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential
- Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer